Cargando…
Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis
CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor (ETI) has been approved for people with CF and at least one F508del allele in Europe. In the US, the ETI label has been expanded to 177 rare CFTR mutations responsive in Fischer rat thyroid cells, including G85E, but not N1303K. However, k...
Autores principales: | Graeber, Simon Y., Balázs, Anita, Ziegahn, Niklas, Rubil, Tihomir, Vitzthum, Constanze, Piehler, Linus, Drescher, Marika, Seidel, Kathrin, Rohrbach, Alexander, Röhmel, Jobst, Thee, Stephanie, Duerr, Julia, Mall, Marcus A., Stahl, Mirjam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418744/ https://www.ncbi.nlm.nih.gov/pubmed/37569738 http://dx.doi.org/10.3390/ijms241512365 |
Ejemplares similares
-
Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
por: Piehler, Linus, et al.
Publicado: (2023) -
Novel CFTR modulator combinations maximise rescue of G85E and N1303K in rectal organoids
por: Ensinck, Marjolein M., et al.
Publicado: (2022) -
Age-Related Differences in Structure and Function of Nasal Epithelial Cultures From Healthy Children and Elderly People
por: Balázs, Anita, et al.
Publicado: (2022) -
Potential of Intestinal Current Measurement for Personalized Treatment of Patients with Cystic Fibrosis
por: Graeber, Simon Y., et al.
Publicado: (2021) -
Rescue of NBD2 Mutants N1303K and S1235R of CFTR by Small-Molecule Correctors and Transcomplementation
por: Rapino, Daniele, et al.
Publicado: (2015)